Marc Suárez-Calvet, MD, PhD, Barcelonaβeta Brain Research Center (BBRC), Barcelona, Spain, discusses the ongoing search for plasma biomarkers that accurately detect preclinical Alzheimer’s disease (AD). Findings from Dr Suárez-Calvet’s lab and others suggest that plasma phosphorylated tau-231 (p-tau231) detects amyloid pathology earlier than other p-tau biomarkers. It is thought that plasma p-tau levels may be useful as pre-screening tools to identify patients at-risk groups in the very earliest stages, in order to enrich clinical trial populations. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
